{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Xenetic Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"XBIO"},"Address":{"label":"Address","value":"40 SPEEN STREET,SUITE 102, FRAMINGHAM, Massachusetts, 01701, United States"},"Phone":{"label":"Phone","value":"+1 781 778-7720"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer."},"CompanyUrl":{"label":"Company Url","value":"https://www.xeneticbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"James F. Parslow","title":"Secretary, Chief Executive & Financial Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}